103 related articles for article (PubMed ID: 29615345)
21. Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.
Shi Q; Canada EJ; Xu Y; Warshawsky AM; Etgen GJ; Broderick CL; Clutinger CK; Irwin LA; Laurila ME; Montrose-Rafizadeh C; Oldham BA; Wang M; Winneroski LL; Xie C; York JS; Yumibe NP; Zink RW; Mantlo N
Bioorg Med Chem Lett; 2007 Dec; 17(24):6744-9. PubMed ID: 18029178
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potential PPAR γ Agonists as Hypoglycemic Agents: Molecular Docking Approach.
Mishra GP; Sharma R
Interdiscip Sci; 2016 Sep; 8(3):220-8. PubMed ID: 26374652
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
Nazreen S; Alam MS; Hamid H; Yar MS; Shafi S; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Ali Y; Kharbanda C; Pillai KK
Eur J Med Chem; 2014 Nov; 87():175-85. PubMed ID: 25255433
[TBL] [Abstract][Full Text] [Related]
24. Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Nazreen S; Alam MS; Hamid H; Yar MS; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai KK
Bioorg Med Chem Lett; 2014 Jul; 24(14):3034-42. PubMed ID: 24890090
[TBL] [Abstract][Full Text] [Related]
25. In silico identification of potential drug compound against Peroxisome proliferator-activated receptor-gamma by virtual screening and toxicity studies for the treatment of Diabetic Nephropathy.
Singh S; Mohanty A
J Biomol Struct Dyn; 2018 May; 36(7):1776-1787. PubMed ID: 28539091
[TBL] [Abstract][Full Text] [Related]
26. Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.
Le Naour M; Leclerc V; Farce A; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Lonchampt M; Dacquet C; Ktorza A; Berthelot P; Lebegue N
ChemMedChem; 2012 Dec; 7(12):2179-93. PubMed ID: 23047286
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
28. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
Ibrahim MK; Eissa IH; Abdallah AE; Metwaly AM; Radwan MM; ElSohly MA
Bioorg Med Chem; 2017 Feb; 25(4):1496-1513. PubMed ID: 28117121
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
Henke BR; Adkison KK; Blanchard SG; Leesnitzer LM; Mook RA; Plunket KD; Ray JA; Roberson C; Unwalla R; Willson TM
Bioorg Med Chem Lett; 1999 Dec; 9(23):3329-34. PubMed ID: 10612594
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
Sæther T; Paulsen SM; Tungen JE; Vik A; Aursnes M; Holen T; Hansen TV; Nebb HI
Eur J Med Chem; 2018 Jul; 155():736-753. PubMed ID: 29940464
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis.
Hopkins CR; O'neil SV; Laufersweiler MC; Wang Y; Pokross M; Mekel M; Evdokimov A; Walter R; Kontoyianni M; Petrey ME; Sabatakos G; Roesgen JT; Richardson E; Demuth TP
Bioorg Med Chem Lett; 2006 Nov; 16(21):5659-63. PubMed ID: 16919947
[TBL] [Abstract][Full Text] [Related]
33. PPAR-γ agonistic metabolites from the ascidian Herdmania momus.
Li JL; Xiao B; Park M; Yoo ES; Shin S; Hong J; Chung HY; Kim HS; Jung JH
J Nat Prod; 2012 Dec; 75(12):2082-7. PubMed ID: 23189988
[TBL] [Abstract][Full Text] [Related]
34. Rational design and synthesis of some PPAR-γ agonists: Substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones.
Chhajed SS; Chaskar S; Kshirsagar SK; Haldar GM; Kar Mahapatra D
Comput Biol Chem; 2017 Apr; 67():260-265. PubMed ID: 28193552
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
36. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
37. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
[TBL] [Abstract][Full Text] [Related]
38. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H
Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects.
Calabrò P; Samudio I; Safe SH; Willerson JT; Yeh ET
J Vasc Res; 2005; 42(6):509-16. PubMed ID: 16155367
[TBL] [Abstract][Full Text] [Related]
40. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
